抗BCMA/GPRC5D双特异性CAR-T治疗伴骨外髓外病变的复发难治多发性骨髓瘤
这项单臂、开放标签、2期试验纳入37例伴骨外髓外病变的复发难治多发性骨髓瘤患者,给予抗BCMA/GPRC5D双特异性CAR-T细胞(2.0×10^6/kg)。中位随访10.1个月时,36例(97%)获得总体反应且MRD阴性,16例(43%)达严格完全缓解;中位无进展生存5.8个月,中位总生存未达到。安全性总体可控。
要点
- 伴骨外髓外病变的复发难治骨髓瘤患者中,抗BCMA/GPRC5D双特异性CAR-T的总体反应率和MRD阴性率均达97%。
- 中位无进展生存期为5.8个月(95%CI 2.2-9.4),中位总生存未达到。
- 细胞因子释放综合征发生率为73%,均为1-2级;≥3级不良事件以血液学毒性为主。
核心结论
- 抗BCMA/GPRC5D双特异性CAR-T细胞在伴骨外髓外病变的复发难治多发性骨髓瘤患者中诱导了高缓解率,且安全性可控。
研究设计与样本
- 单臂、开放标签、2期试验,纳入37例伴骨外髓外病变的复发难治多发性骨髓瘤患者。
- 抗BCMA/GPRC5D双特异性CAR-T细胞按2.0×10^6 CAR-T细胞/kg给药。
- 试验注册号NCT05509530,中位随访10.1个月(四分位距6.4-19.1)。
主要发现
- 36/37例(97%)获得总体反应且可测量残留病阴性,其中16例(43%)达严格完全缓解。
- 中位无进展生存期为5.8个月(95%CI 2.2-9.4),中位总生存未达到。
- ≥3级不良事件最常见为血液学毒性(除淋巴细胞减少外,37/37例)。
- 2例(5%)发生免疫效应细胞相关神经毒性综合征,分别为1级和3级。
临床怎么用
- 对于伴骨外髓外病变的复发难治多发性骨髓瘤患者,抗BCMA/GPRC5D双特异性CAR-T可作为高缓解率的治疗选择,但需关注血液学毒性和细胞因子释放综合征管理。
局限性
- 单臂、开放标签设计,无对照组,样本量37例,随访时间中位10.1个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with relapsed or refractory multiple myeloma (RRMM) with extraosseous extramedullary disease (EMD) have inferior outcomes and lack effective therapies. We developed anti-B-cell maturation antigen (anti-BCMA)/G protein-coupled receptor, class C group 5 member D (GPRC5D) bispecific chimeric antigen receptors (CARs) to investigate the activity and safety of the CAR T cells in patients with extraosseous EMD. In this single-arm, open-label, phase 2 trial, we enrolled 37 patients with RRMM with extraosseous EMD, and anti-BCMA/GPRC5D bispecific CAR T cells were administered at 2.0 × 106 CAR T cells per kg. At a median follow-up of 10.1 months (interquartile range, 6.4-19.1), 36 of 37 patients (97%) obtained an overall response and measurable residual disease negativity, including 16 (43%) with stringent complete response. The median progression-free survival was 5.8 months (95% confidence interval, 2.2-9.4), and the median overall survival was not reached. The most common grade 3 or worse adverse events were hematologic toxicities (except lymphopenia; 37/37). Twenty-seven patients (73%) experienced cytokine release syndrome, all cases of which were grade 1 or 2. Two patients (5%) had grade 1 or 3 immune effector cell-associated neurotoxicity syndrome. These findings support that anti-BCMA/GPRC5D bispecific CAR T cells induced a high response rate in patients with RRMM with extraosseous EMD, and the safety profile was manageable. This ongoing trial is registered at www.clinicaltrials.gov as NCT05509530.
引用
- Zhou D, Qi Y, Ma S, et al. Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease. Blood. 2026. PMID: 42166352. doi:10.1182/blood.2026033506
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。